|
Demographic and clinical characteristics, and drug treatment of patients with preserved and with impaired left ventricular systolic function. |
|||
| Variables† |
Patients with preserved systolic function (n = 519) |
Patients with impaired systolic function (n = 23) |
P* |
|
|
|||
| Patient characteristics |
|||
| Age, years, |
63 (62 to 63) |
69 (66 to 73) |
0.003 |
| Male, % |
57 |
70 |
0.241 |
| BMI |
29 (29 to 30) |
29 (27 to 31) |
0.854 |
| Systolic BP, mm Hg |
151 (149 to 152) |
146 (138 to 155) |
0.342 |
| Diastolic BP, mm Hg |
86 (85 to 86) |
83 (78 to 89) |
0.361 |
| Ejection Fraction, % |
61 (60 to 62) |
41 (38 to 45) |
<0.001 |
| NT-proBNP, pg/ml |
218 (174 to 259) |
1154 (236 to 2072) |
<0.001 |
| Symptoms |
|||
| Dyspnea at exertion, % |
34 |
74 |
<0.001 |
| Dyspnea at rest, % |
1 |
9 |
0.003 |
| Ankle swelling, % |
33 |
74 |
<0.001 |
| Medical history |
|||
| Diabetes, % |
31 |
39 |
0.400 |
| Hypertension, % |
86 |
96 |
0.184 |
| Hyperlipidemia, % |
51 |
74 |
0.032 |
| CAD, % |
29 |
65 |
<0.001 |
| Myocardial infarction, % |
7 |
22 |
0.019 |
| Fam. history heart disease, % |
42 |
57 |
0.168 |
| Drug treatment |
|||
| Diuretics, % |
42 |
74 |
0.003 |
| β blockers, % |
57 |
74 |
0.105 |
| Calcium channel blockers, % |
23 |
22 |
0.928 |
| ACE inhibitors, % |
46 |
52 |
0.564 |
| AT1 blockers, % |
16 |
26 |
0.201 |
| Lipid lowerings agents, % |
35 |
74 |
<0.001 |
|
* T-Test or χ2-Test. † values in mean (95% confidence interval) unless otherwise indicated. BMI Body Mass Index; BP blood pressure; CAD coronary artery disease; ACE angiotension converting enzyme, AT1 blocker angiotensin II type 1 receptor blocker. | |||
Koschack et al. BMC Family Practice 2008 9:14 doi:10.1186/1471-2296-9-14 |
|||